Abeona Therapeutics bought a drug for treating eosinophilic esophagitis and raised $30 million in funding.

Nov 9, 2026, 11:16 AM ETDealRead the original at Benzinga

Neutral

Abeona's reported loss was smaller than expected, it raised cash, and ZEVASKYN sales rose, but quarterly revenue missed estimates. The new drug needs a later trial, and share issuance plus possible future payments leave no clear change to its outlook.

ABEO · Abeona Therapeutics Inc.

AI read · Neutral

The AI's read

The new drug could broaden Abeona's treatment options, and the added cash can support its work. ZEVASKYN sales grew, and qualifying hospitals can receive extra Medicare payments. But the new drug still needs a Phase 3 trial, with possible payments tied to approval and sales. The share issues give current owners smaller pieces, and quarterly revenue missed estimates.

Get alerts for ABEO

Follow Abeona Therapeutics Inc. (ABEO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ABEO

Free on the App Store and Google Play, or on the web.